Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis
| Autor: | Sylvie Fabre, Dominique Baeten, Isabelle Touitou, Meryem Ammari, Florence Apparailly, Guillaume Cartron, Yves-Marie Pers, Christian Jorgensen, Isabelle Duroux-Richard |
|---|---|
| Přispěvatelé: | Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service d'immuno-rhumatologie[Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Dpt of Clinical Immunology & Rheumatology [Amsterdam], Amsterdam and Atrium Medical Center, Dynamique des interactions membranaires normales et pathologiques (DIMNP), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Montpellier 1 (UM1), Philips, Alexandre, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Amsterdam institute for Infection and Immunity, Clinical Immunology and Rheumatology |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Male
Article Subject Inflammatory arthritis [SDV]Life Sciences [q-bio] Immunology Arthritis Inflammation Arthritis Rheumatoid Antibodies Monoclonal Murine-Derived Predictive Value of Tests lcsh:Pathology medicine Humans ComputingMilieux_MISCELLANEOUS Aged business.industry Cell Biology Middle Aged medicine.disease 3. Good health [SDV] Life Sciences [q-bio] MicroRNAs Treatment Outcome Gene Expression Regulation Antirheumatic Agents Rheumatoid arthritis Predictive value of tests Chronic Disease Monoclonal Clinical Study Biomarker (medicine) Female Rituximab medicine.symptom business Biomarkers lcsh:RB1-214 medicine.drug |
| Zdroj: | Mediators of Inflammation Mediators of Inflammation, Hindawi Publishing Corporation, 2014, 2014, pp.1-9. ⟨10.1155/2014/342524⟩ Mediators of Inflammation, 2014, 2014, pp.1-9. ⟨10.1155/2014/342524⟩ Mediators of inflammation, 2014. Hindawi Publishing Corporation Mediators of Inflammation, Vol 2014 (2014) |
| ISSN: | 0962-9351 1466-1861 |
| Popis: | Although biologic therapies have changed the course of rheumatoid arthritis (RA), today’s major challenge remains to identify biomarkers to target treatments to selected patient groups. Circulating micro(mi)RNAs represent a novel class of molecular biomarkers whose expression is altered in RA. Our study aimed at quantifying miR-125b in blood and serum samples from RA patients, comparing healthy controls and patients with other forms of rheumatic diseases and arthritis, and evaluating its predictive value as biomarker for response to rituximab. Detectable levels of miR-125b were measured in total blood and serum samples and were significantly elevated in RA patients compared to osteoarthritic and healthy donors. The increase was however also found in patients with other forms of chronic inflammatory arthritis. Importantly, high serum levels of miR-125b at disease flare were associated with good clinical response to treatment with rituximab three months later (P=0.002). This predictive value was not limited to RA as it was also found in patients with B lymphomas. Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text